Anxiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity
- PMID: 20728278
- DOI: 10.1016/j.psyneuen.2010.07.021
Anxiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity
Abstract
A number of neurosteroids have been demonstrated to exert anxiolytic properties by means of a positive modulation of inhibitory GABAergic neurotransmission. The observation that neurosteroid synthesis can be pharmacologically regulated by ligands to the mitochondrial translocator protein (TSPO) has prompted the search for new, more selective TSPO ligands able to stimulate steroidogenesis with great efficacy. In the present study, the potential anxiolytic activity of a selective TSPO ligand, N,N-di-n-propyl-2-(4-methylphenyl)indol-3-ylglyoxylamide (MPIGA), was tested by means of the elevated plus maze paradigm. Moreover, the in vitro effects on synaptoneurosomal GABA(A) receptor (GABA(A)R) activity exerted by the conditioned salt medium from MPIGA-treated ADF human glial cells were investigated. MPIGA (30mg/kg) was found to affect rats' performance in the elevated plus maze test significantly, leading to an increase in both entries and time spent in the open arms. This same dose of MPIGA had no effect on rats' spontaneous exploratory activity. The conditioned salt medium from MPIGA-treated ADF cells potentiated the (36)Cl(-) uptake into cerebral cortical synaptoneurosomes. The exposure of ADF cells to MPIGA stimulated the production of pregnelonone derivatives including allopregnanolone, one of the major positive GABA(A)R allosteric modulator. In conclusion, the TSPO ligand MPIGA is a promising anxiolytic drug. The mechanism of action by which MPIGA exerts its anxiolytic activity was identified in the stimulation of endogenous neurosteroid production, which in turn determined a positive modulation of GABA(A)R activity, thus opening the way to the potential use of this TSPO ligand in anxiety and depressive disorders.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
TSPO ligand residence time influences human glioblastoma multiforme cell death/life balance.Apoptosis. 2015 Mar;20(3):383-98. doi: 10.1007/s10495-014-1063-3. Apoptosis. 2015. PMID: 25413799
-
Medicinal chemistry of indolylglyoxylamide TSPO high affinity ligands with anxiolytic-like effects.Curr Top Med Chem. 2012;12(4):333-51. doi: 10.2174/156802612799078766. Curr Top Med Chem. 2012. PMID: 22204487 Review.
-
Translocator protein as a promising target for novel anxiolytics.Curr Top Med Chem. 2012;12(4):270-85. doi: 10.2174/156802612799078720. Curr Top Med Chem. 2012. PMID: 22204481 Review.
-
Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile.J Neuroendocrinol. 2012 Jan;24(1):82-92. doi: 10.1111/j.1365-2826.2011.02166.x. J Neuroendocrinol. 2012. PMID: 21609361 Review.
-
Design, Synthesis and Anxiolytic Activity Evaluation of N-Acyltryptophanyl- Containing Dipeptides, Potential TSPO Ligands.Med Chem. 2019;15(4):383-399. doi: 10.2174/1573406415666181119164846. Med Chem. 2019. PMID: 30457052
Cited by
-
Carbonic anhydrase activation profile of indole-based derivatives.J Enzyme Inhib Med Chem. 2021 Dec;36(1):1783-1797. doi: 10.1080/14756366.2021.1959573. J Enzyme Inhib Med Chem. 2021. PMID: 34340630 Free PMC article.
-
The antidepressant-like activity of AC-5216, a ligand for 18KDa translocator protein (TSPO), in an animal model of diabetes mellitus.Sci Rep. 2016 Nov 25;6:37345. doi: 10.1038/srep37345. Sci Rep. 2016. PMID: 27886206 Free PMC article.
-
TSPO ligand residence time: a new parameter to predict compound neurosteroidogenic efficacy.Sci Rep. 2016 Jan 11;6:18164. doi: 10.1038/srep18164. Sci Rep. 2016. PMID: 26750656 Free PMC article.
-
Translocator Protein Ligand PIGA1138 Reduces Disease Symptoms and Severity in Experimental Autoimmune Encephalomyelitis Model of Primary Progressive Multiple Sclerosis.Mol Neurobiol. 2022 Mar;59(3):1744-1765. doi: 10.1007/s12035-022-02737-2. Epub 2022 Jan 11. Mol Neurobiol. 2022. PMID: 35018577
-
Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.Nat Rev Drug Discov. 2010 Dec;9(12):971-88. doi: 10.1038/nrd3295. Nat Rev Drug Discov. 2010. PMID: 21119734 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials